Key result
Validated HPLC method successfully quantifies newly isolated process-related impurity G in furosemide.
Why the study?
During the preparation of furosemide, a new process-related impurity G was detected in pilot batches, necessitating its isolation, characterization, and the validation of an HPLC method for its determination.
The study identifies a novel process-related impurity in furosemide and provides a validated HPLC method for its quantification, ensuring pharmaceutical quality.
Alerts manufacturers to monitor impurity G in furosemide; leaves open any clinical safety impact pending further data.
Furosemide is a widely used loop diuretic in the treatment of congestive heart failure and edema. During the preparation of furosemide, a new process-related impurity G in the levels ranging from 0.08% to 0.13% was detected in pilot batches by a new high performance liquid chromatography (HPLC) method. The new impurity was isolated and characterized by comprehensive analysis of FT-IR, Q-TOF/LC-MS, 1D-NMR (1H, 13C, and DEPT), and 2D-NMR (1H-1H-COSY, HSQC, and HMBC) spectroscopy data. The possible formation pathway of impurity G was also discussed in detail. Moreover, a novel HPLC method was developed and validated for the determination of impurity G and the other six known impurities registered in the European Pharmacopoeia as per ICH guidelines. The HPLC method was validated with respect to system suitability, linearity, the limit of quantitation, the limit of detection, precision, accuracy, and robustness. The characterization of impurity G and the validation of its quantitative HPLC method were reported for the first time in this paper. Finally, the toxicological properties of impurity G were predicted by the in silico webserver ProTox-II.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2023) studied this question. HPLC method for Furosemide Impurity G was evaluated on Detection and quantification of Impurity G. A novel process-related impurity G in furosemide was isolated, characterized as 2,4-bis((furan-2-ylmethyl)amino)benzene sulfonamide, and a validated HPLC method was developed for its quantification.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: